A Phase II Study of Ivonescimab Combined With Iza-bren in Patients With Advanced Non-Small Cell Lung Cancer. (PEGASUS-Lung)
A Multicenter, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of Ivonescimab Combined With Iza-bren Brengitecan in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Resistant to Third-Generation EGFR-TKIs
This is a prospective, multicenter, open-label, single-arm phase II clinical study evaluating the efficacy and safety of ivonescimab (a PD-1/VEGF bispecific antibody) combined with Iza-bren (BL-B01D1; izalontamab brengitecan, an EGFR×HER3 bispecific antibody-drug conjugate) in patients aged ≥18 years with histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations (exon 19 deletion or L858R) who have imaging-confirmed disease progression during or after prior third-generation EGFR-TKI therapy. A total of 43 subjects will be enrolled at 3 centers. The primary endpoint is progression-free survival (PFS). Other efficacy endpoints include ORR, confirmed ORR, DCR, DoR, OS, 6- and 12-month PFS rates, and 12- and 24-month OS rates. Safety and tolerability will be assessed, and exploratory analyses will evaluate immune markers, HER3 expression, and EGFR resistance molecular subtypes in relation to clinical efficacy. Treatment is given every 3 weeks: ivonescimab 20 mg/kg intravenously on Day 1; Iza-bren 2.5 mg/kg intravenously on Days 1 and 8. Ivonescimab is infused first, followed by Iza-bren after an interval of ≥30 minutes. Treatment continues until disease progression, intolerable toxicity, initiation of new anti-cancer therapy, death, withdrawal of consent, or a maximum of 24 months of treatment.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Study Design Prospective, multicenter, single-arm phase II study Objectives
Primary objective:
To evaluate the efficacy and safety of ivonescimab combined with Iza-bren in patients with EGFR-sensitizing mutation-positive advanced non-squamous NSCLC after progression on third-generation EGFR-TKIs.
Secondary objectives:
- To explore the correlation of baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy;
- To analyze efficacy differences in the baseline brain metastasis subgroup and among different EGFR mutation subtypes (19del/L858R);
- To explore the association of tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) with PFS and OS outcomes.
Endpoints
- Progression-free survival (PFS), objective response rate (ORR), confirmed objective response rate (cORR), and overall survival (OS); to calculate 6-month and 12-month PFS rates and 12-month and 24-month OS rates;
- To evaluate the overall safety and tolerability of the combination regimen, and to describe the type, incidence, severity (CTCAE 6.0), duration, management measures, and outcomes of treatment-related adverse events (TRAEs).
Study Population Pathologically confirmed non-squamous NSCLC harboring EGFR-sensitizing mutations, with imaging-confirmed progression after third-generation EGFR-TKI therapy (age ≥18 years, any sex).
Inclusion/Exclusion Criteria
Inclusion criteria (all must be met):
-
Voluntary written informed consent and ability to comply with study procedures; age ≥18 years, any sex.
-
Histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC (AJCC 8th edition).
-
EGFR-sensitizing mutation (exon 19 deletion or L858R) confirmed by tissue, cytology, or plasma ctDNA; concomitant resistance mutations such as T790M, C797S, and 861Q are allowed.
-
Prior standard treatment with a third-generation EGFR-TKI (osimertinib, almonertinib, furmonertinib, etc.), with imaging-confirmed disease progression during or after treatment.
-
ECOG performance status 0 or 1; expected survival ≥3 months.
-
At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm; lymph node short diameter ≥15 mm).
-
Without transfusion or use of colony-stimulating factors, thrombopoietin, or any cell growth factor within 14 days before screening tests, organ function must meet the following criteria:
- Hematology: ANC ≥1.5×10⁹/L; PLT ≥75×10⁹/L; Hb ≥90 g/L;
- Liver function: AST/ALT ≤2.5×ULN (≤5×ULN in patients with liver metastases); total bilirubin ≤1.5×ULN;
- Renal function: creatinine ≤1.5×ULN; urine protein ≤2+ or ≤1000 mg/24 h;
- Coagulation: INR and APTT ≤1.5×ULN.
-
Toxicities from prior anti-cancer therapy have recovered to ≤ grade 1 per NCI-CTCAE v6.0 (except alopecia, fatigue, pigmentation, hypothyroidism stable on hormone replacement, grade 2 peripheral neuropathy after chemotherapy, and other exceptions specified in the inclusion criteria).
-
Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test is negative at screening for women of childbearing potential.
Exclusion criteria (any one excludes):
- Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
- Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
- Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
- Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
- Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
- Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
- Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
- QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
- Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
- Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
- Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
- Pregnant or lactating women.
- Concurrent participation in other interventional anti-cancer clinical trials.
- Investigator considers the patient unsuitable for participation in this study. Randomization and Intervention Plan Ivonescimab: 20 mg/kg, intravenous infusion on Day 1 of each cycle; first infusion time 60±10 minutes; for patients unable to tolerate a 60-minute infusion, the infusion time may be extended up to 120 minutes; if no infusion reaction occurs, subsequent cycles may be shortened to 30-60 minutes.
Iza-bren: 2.5 mg/kg, intravenous drip on Days 1 and 8 of each cycle; first infusion time ≥120 minutes; after tolerance, it may be adjusted to 60-120 minutes.
Follow-up Plan Treatment-period follow-up: once before each treatment cycle to assess safety and compliance; efficacy follow-up with imaging every 6 weeks.
End-of-treatment (EOT) visit: 28±7 days after the last dose; complete physical examination, laboratory tests, imaging assessment (conditional), and AE follow-up.
Survival follow-up: every 90±7 days after EOT, via outpatient visit, telephone, WeChat, etc.; record survival status, subsequent anti-cancer treatment, and living status.
Sample Size Calculation A total of 43 subjects are planned. Based on the one-sample log-rank method: the expected number of events under the alternative hypothesis is 32.26; with 38 subjects enrolled, the asymptotic power can reach 80.78%, meeting the prespecified power requirement; considering a 10% dropout rate, the final sample size is 43.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Fuming Qiu
- Numero di telefono: +86-13858005908
- Email: qiufuming@zju.edu.cn
Backup dei contatti dello studio
- Nome: Youping Wang
- Numero di telefono: +86-18358147489
- Email: 2315124@zju.edu.cn
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Voluntary written informed consent, age ≥18 years, any sex.
-
Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous NSCLC (AJCC 8th edition).
-
Confirmed EGFR-sensitizing mutation (Exon 19 deletion or L858R) in tissue, cytology, or plasma ctDNA. Concomitant resistance mutations (e.g., T790M, C797S, 861Q) are allowed.
-
Prior standard treatment with a third-generation EGFR-TKI (e.g., osimertinib, almonertinib, furmonertinib), with imaging-confirmed disease progression during or after treatment.
-
ECOG performance status of 0 or 1; expected survival ≥3 months.
-
At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm, or lymph node short diameter ≥15 mm).
-
Adequate organ function (without transfusion or growth factors within 14 days prior to screening):
Hematology: ANC ≥1.5×10^9/L; PLT ≥75×10^9/L; Hb ≥90 g/L. Liver: AST/ALT ≤2.5×ULN (≤5×ULN for liver metastases); Total bilirubin ≤1.5×ULN.
Renal: Creatinine ≤1.5×ULN; Urine protein ≤2+ or ≤1000 mg/24h. Coagulation: INR and APTT ≤1.5×ULN.
-
Prior treatment-related toxicities have recovered to ≤ Grade 1 per NCI-CTCAE v6.0 (except for alopecia, fatigue, pigmentation, stable hypothyroidism on hormone replacement, or grade 2 peripheral neuropathy from chemotherapy).
-
Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test must be negative for women of childbearing potential at screening.
Exclusion Criteria:
- Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
- Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
- Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
- Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
- Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
- Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
- Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
- QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
- Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
- Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
- Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
- Pregnant or lactating women.
- Concurrent participation in other interventional anti-cancer clinical trials.
- Investigator considers the patient unsuitable for participation in this study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Ivonescimab combined with Izabren
Patients receive ivonescimab (20 mg/kg IV on Day 1) and Iza-bren (2.5 mg/kg IV on Days 1 and 8) every 3 weeks (21-day cycle). Treatment continues until disease progression, unacceptable toxicity, or up to 24 months. |
20 mg/kg, intravenous infusion on Day 1 of each 21-day cycle.
Altri nomi:
2.5 mg/kg, intravenous drip on Days 1 and 8 of each 21-day cycle. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Progression-Free Survival (PFS)
Lasso di tempo: From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).
|
PFS is defined as the time from the first dose of study treatment to the first documented disease progression (evaluated by investigators according to RECIST v1.1) or death from any cause, whichever occurs first. Participants who are alive and progression-free at the time of analysis will be censored at the last adequate tumor assessment. |
From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate (ORR)
Lasso di tempo: Up to approximately 24 months.
|
The proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed by investigators according to RECIST v1.1. |
Up to approximately 24 months.
|
|
Confirmed Objective Response Rate (cORR)
Lasso di tempo: Up to approximately 24 months.
|
The proportion of participants with a confirmed CR or PR (confirmed by repeat imaging at least 4 weeks later), as assessed by investigators according to RECIST v1.1. |
Up to approximately 24 months.
|
|
Disease Control Rate (DCR)
Lasso di tempo: Up to approximately 24 months.
|
The proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed by investigators according to RECIST v1.1. |
Up to approximately 24 months.
|
|
Duration of Response (DoR)
Lasso di tempo: From first documented response to disease progression or death (up to approximately 24 months).
|
The time from the first documentation of CR or PR to the first documentation of disease progression or death from any cause, whichever occurs first. |
From first documented response to disease progression or death (up to approximately 24 months).
|
|
Overall Survival (OS)
Lasso di tempo: From the first dose of study treatment to death from any cause (up to approximately 42 months).
|
The time from the first dose of study treatment to death from any cause. |
From the first dose of study treatment to death from any cause (up to approximately 42 months).
|
|
6-month and 12-month PFS Rates
Lasso di tempo: At 6, 12 months after the first dose.
|
The probability of participants remaining progression-free at specific time points, estimated using the Kaplan-Meier method. |
At 6, 12 months after the first dose.
|
|
12-month and 24-month OS Rates
Lasso di tempo: At 12 and 24 months after the first dose.
|
The probability of participants remaining alive at specific time points, estimated using the Kaplan-Meier method. |
At 12 and 24 months after the first dose.
|
|
Safety and Tolerability (Incidence of Treatment-Related Adverse Events)
Lasso di tempo: From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).
|
The incidence, severity (graded by NCI-CTCAE v6.0), duration, and management of treatment-related adverse events (TRAEs). |
From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Correlation of Biomarkers with Clinical Efficacy
Lasso di tempo: Baseline, during treatment, and up to approximately 42 months.
|
To explore the correlation between baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy (e.g., ORR, PFS). |
Baseline, during treatment, and up to approximately 42 months.
|
|
Efficacy Analysis in Specific Subgroups
Lasso di tempo: Up to approximately 42 months.
|
To analyze the differences in efficacy (such as ORR and PFS) among patients with baseline brain metastases and different EGFR mutation subtypes (exon 19 deletion vs. L858R). |
Up to approximately 42 months.
|
|
Association of Immune Markers with Survival Outcomes
Lasso di tempo: Up to approximately 42 months.
|
To explore the association between tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) and survival outcomes (PFS and OS). |
Up to approximately 42 months.
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Pubblicazioni e link utili
Pubblicazioni generali
- Wei Q, Li P, Yang T, Zhu J, Sun L, Zhang Z, Wang L, Tian X, Chen J, Hu C, Xue J, Ma L, Shimura T, Fang J, Ying J, Guo P, Cheng X. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024 Jan 4;17(1):1. doi: 10.1186/s13045-023-01509-2.
- HARMONi-A Study Investigators; Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K, Song Q, Du X, Sun Y, Li W, Sun L, Wang Z, Yang K, Fan Y, Liu B, Zhao H, Hu Y, Jia L, Xu S, Yi T, Lv D, Lan H, Li M, Liang W, Wang Y, Yang H, Jia Y, Chen Y, Lu J, Shi M, Liu C, Zhou M, Zhou J, Liu X, Zhou N, He M, Dong X, Chen H, Chen Y, Su H, Li X, Zhang Z, Yang L, Liu Y, Chen L, Hou X, Zhang Y, Guo J, Ma R, Lu H, Wu D, Feng W, Li W, Huang J, Wang Y, Song X, Peng J, Liu L, Guo Y, Li W, Xia M, Lu D, Hu M, Wang ZM, Li B, Xia MY, Zhang L. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. JAMA. 2026 Jul 28;336(4):306-314. doi: 10.1001/jama.2026.7745.
- Zhou K, Liu X, Zhu H. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025 Nov 3;18(1):96. doi: 10.1186/s13045-025-01752-9.
- Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Janne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.
- Trontzas IP, He M, Wurtz A, Robbins CJ, Robinson N, Bates K, Liu M, Aung TN, Scott L, Chan N, Burela S, Schillo J, Liebler DC, Hill S, Morrison RD, Vathiotis I, Syrigos KN, Goldberg SB, Politi K, Rimm DL. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Jul 1;31(13):2767-2776. doi: 10.1158/1078-0432.CCR-24-3347.
- Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, Lamszus K, Goy Y, Petersen C, Westphal M, Glatzel M, Riethdorf S, Pantel K, Wikman H. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Sci Rep. 2019 May 15;9(1):7406. doi: 10.1038/s41598-019-43678-6.
- Gao L, Zhang Y, Feng M, Shen M, Yang L, Wei B, Zhou Y, Zhang Z. HER3: Updates and current biology function, targeted therapy and pathologic detecting methods. Life Sci. 2024 Nov 15;357:123087. doi: 10.1016/j.lfs.2024.123087. Epub 2024 Oct 2.
- Zhao J, Xu W, Zhou F, Zhang X, Zhou M, Miao D, Yu L, Zhang Y, Fan J, Zhou C, Li W, Mok T, Le X, Li M, Xia Y. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches. Nat Rev Clin Oncol. 2026 Jan;23(1):63-83. doi: 10.1038/s41571-025-01085-z. Epub 2025 Nov 11.
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014 Aug;14(8):535-46. doi: 10.1038/nrc3775.
- Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026 Jul-Aug;76(4):e70090. doi: 10.3322/caac.70090.
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IIT-2026-10-22
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .